Form D · Biotechnology

EnZeta Immunotherapies, Inc.

Coral Gables, FL · CIK 0001994145

Offering snapshot reported Mar 6, 2026 · SEC filing

Reported sold
$840K
Offering amount: $2.37M
Investors reported
10
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Feb 17, 2025
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$420K$840KFeb 20, 2025: $200,000.00Feb 20, 2025Mar 6, 2026: $840,000.00Mar 6, 2026

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$200,000 → $840,000
  • Reported investors3 → 10
  • Minimum accepted$50,000 → $0

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 6, 2026Amendment$840,000$640,000vs Feb 20, 202510SEC filing
Feb 20, 2025Initial$200,000No comparison3SEC filing
Sep 29, 2023Initial$5,000No comparison5SEC filing
Sep 26, 2023Initial$10,000No comparison2SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-538757

Source: Form D, filed Mar 6, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Paul Kelly Director, Executive
Traversa Sergio Director
Sergio Traversa Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
122 Sevilla Ave # 919
Coral Gables, FL, 33134